Mar 12, 2014
From the Healthcare & Life Sciences Institute
The Centers for Medicare & Medicaid services (CMS) has proposed changes to the Medicare Advantage (Part C or "MA") and Prescription Drug (Part D or "PD") (collectively, MAPD) programs. The proposed changes create financial, operational and compliance-related challenges for health plans offering the MA and PD plans, but physicians and life sciences companies are also anticipated to be directly impacted.
Health plans and MAPD sponsors are currently preparing their 2015 MAPD bids, due June 2014, in order to meet the proposed 2015 effective date. This is a high-level summary of the proposed changes, and the implications discussed are reflective of the experience and observations of KPMG professionals working with our health industry clients.